{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:00:07Z","timestamp":1788296407771,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00252283"],"award-info":[{"award-number":["RS-2023-00252283"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024838","name":"Samsung Medical Center, Sungkyunkwan University","doi-asserted-by":"publisher","award":["SMO1240501"],"award-info":[{"award-number":["SMO1240501"]}],"id":[{"id":"10.13039\/501100024838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002647","name":"Sungkyunkwan University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002647","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10549-026-07906-8","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:54:54Z","timestamp":1770292494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion"],"prefix":"10.1007","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-3931","authenticated-orcid":false,"given":"Tae Hoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-2882","authenticated-orcid":false,"given":"Hyunwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3167-0635","authenticated-orcid":false,"given":"Jeong Yun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-2071","authenticated-orcid":false,"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-8270","authenticated-orcid":false,"given":"Won Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4675-4492","authenticated-orcid":false,"given":"Eun Yoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-6730","authenticated-orcid":false,"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-9212","authenticated-orcid":false,"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1072-8954","authenticated-orcid":false,"given":"Seok Jin","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6130-7570","authenticated-orcid":false,"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-2456","authenticated-orcid":false,"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-7573","authenticated-orcid":false,"given":"Haeyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"6","key":"7906_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J et al (2024) Breast cancer statistics 2024. CA Cancer J Clin 74(6):477\u2013495","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"7906_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4048\/jbc.2023.26.e27","volume":"26","author":"JE Choi","year":"2023","unstructured":"Choi JE, Kim Z, Park CS, Park EH, Lee SB, Lee SK et al (2023) Breast cancer statistics in Korea, 2019. J Breast Cancer 26(3):207\u2013220","journal-title":"J Breast Cancer"},{"issue":"1","key":"7906_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2020.07.001","volume":"21","author":"AM Tufano","year":"2021","unstructured":"Tufano AM, Teplinsky E, Landry CA (2021) Updates in neoadjuvant therapy for triple negative breast cancer. Clin Breast Cancer 21(1):1\u20139","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"7906_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275\u20131281","journal-title":"J Clin Oncol"},{"issue":"28","key":"7906_CR5","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414\u20134422","journal-title":"J Clin Oncol"},{"issue":"7","key":"7906_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/modpathol.2015.53","volume":"28","author":"F Peintinger","year":"2015","unstructured":"Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J et al (2015) Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol 28(7):913\u2013920","journal-title":"Mod Pathol"},{"issue":"11","key":"7906_CR7","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1001\/jamaoncol.2021.3690","volume":"7","author":"WF Symmans","year":"2021","unstructured":"Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L et al (2021) Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial. JAMA Oncol 7(11):1654\u20131663","journal-title":"JAMA Oncol"},{"issue":"1","key":"7906_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D et al (2022) Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23(1):149\u2013160","journal-title":"Lancet Oncol"},{"issue":"3","key":"7906_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030968","volume":"11","author":"E Kuhn","year":"2023","unstructured":"Kuhn E, Gambini D, Despini L, Asnaghi D, Runza L, Ferrero S (2023) Updates on lymphovascular invasion in breast cancer. Biomedicines 11(3):968","journal-title":"Biomedicines"},{"issue":"2","key":"7906_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/01.sla.0000133355.48672.22","volume":"240","author":"SF Schoppmann","year":"2004","unstructured":"Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M et al (2004) Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 240(2):306\u2013312","journal-title":"Ann Surg"},{"issue":"15","key":"7906_CR11","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/cncr.26711","volume":"118","author":"EA Rakha","year":"2012","unstructured":"Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z et al (2012) The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 118(15):3670\u20133680","journal-title":"Cancer"},{"issue":"3","key":"7906_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10549-016-3837-5","volume":"157","author":"YL Liu","year":"2016","unstructured":"Liu YL, Saraf A, Lee SM, Zhong X, Hibshoosh H, Kalinsky K et al (2016) Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 157(3):555\u2013564","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7906_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10549-017-4610-0","volume":"169","author":"AS Hamy","year":"2018","unstructured":"Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J et al (2018) Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. Breast Cancer Res Treat 169(2):295\u2013304","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"7906_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ijrobp.2009.08.049","volume":"78","author":"R Boutrus","year":"2010","unstructured":"Boutrus R, Abi-Raad R, Niemierko A, Brachtel EF, Rizk L, Kelada A et al (2010) Does lymphovascular invasion predict regional nodal failure in breast cancer patients with zero to three positive lymph nodes treated with conserving surgery and radiotherapy? Implications for regional radiation. Int J Radiat Oncol Biol Phys 78(3):793\u2013798","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"7906_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00231-x","volume":"7","author":"D Makower","year":"2021","unstructured":"Makower D, Lin J, Xue X, Sparano JA (2021) Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ Breast Cancer 7(1):20","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"7906_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jso.27523","volume":"129","author":"NK Heater","year":"2024","unstructured":"Heater NK, Somayaji K, Gradishar W (2024) Treatment of residual disease following neoadjuvant therapy in breast cancer. J Surg Oncol 129(1):18\u201325","journal-title":"J Surg Oncol"},{"issue":"5","key":"7906_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100269","volume":"6","author":"N Hou","year":"2021","unstructured":"Hou N, Wu J, Xiao J, Wang Z, Song Z, Ke Z et al (2021) Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy. ESMO Open 6(5):100269","journal-title":"ESMO Open"},{"issue":"1","key":"7906_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mdu508","volume":"26","author":"A Sheri","year":"2015","unstructured":"Sheri A, Smith IE, Johnston SR, A\u2019Hern R, Nerurkar A, Jones RL et al (2015) Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol 26(1):75\u201380","journal-title":"Ann Oncol"},{"issue":"1","key":"7906_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02070-1","volume":"27","author":"RA Leon-Ferre","year":"2025","unstructured":"Leon-Ferre RA, Dimitroff K, Yau C, Giridhar KV, Mukhtar R, Hirst G et al (2025) Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. Breast Cancer Res 27(1):115","journal-title":"Breast Cancer Res"},{"issue":"6","key":"7906_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234191","volume":"15","author":"AS Hamy","year":"2020","unstructured":"Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT et al (2020) Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS ONE 15(6):e0234191","journal-title":"PLoS ONE"},{"key":"7906_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.903372","volume":"12","author":"JY Kim","year":"2022","unstructured":"Kim JY, Oh JM, Lee SK, Yu J, Lee JE, Kim SW et al (2022) Improved prediction of survival outcomes using residual cancer burden in combination with Ki-67 in breast cancer patients underwent neoadjuvant chemotherapy. Front Oncol 12:903372","journal-title":"Front Oncol"},{"issue":"4","key":"7906_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4048\/jbc.2019.22.e49","volume":"22","author":"X Li","year":"2019","unstructured":"Li X, Wang M, Wang M, Yu X, Guo J, Sun T et al (2019) Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy. J Breast Cancer 22(4):497\u2013521","journal-title":"J Breast Cancer"},{"issue":"1","key":"7906_CR23","doi-asserted-by":"publisher","first-page":"13977","DOI":"10.1038\/s41598-025-98176-9","volume":"15","author":"SY Lee","year":"2025","unstructured":"Lee SY, Yoo TK, Lee SB, Kim J, Chung IY, Ko BS et al (2025) Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis. Sci Rep 15(1):13977","journal-title":"Sci Rep"},{"issue":"18","key":"7906_CR24","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"JFE Harrell","year":"1982","unstructured":"Harrell JFE, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247(18):2543\u20132546","journal-title":"JAMA"},{"issue":"8","key":"7906_CR25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41416-020-01251-3","volume":"124","author":"E Laas","year":"2021","unstructured":"Laas E, Labrosse J, Hamy AS, Benchimol G, de Croze D, Feron JG et al (2021) Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore. Br J Cancer 124(8):1421\u20131427","journal-title":"Br J Cancer"},{"issue":"7","key":"7906_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamaoncol.2015.6478","volume":"2","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF et al (2016) The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol 2(7):929\u2013936","journal-title":"JAMA Oncol"},{"issue":"9","key":"7906_CR27","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","volume":"28","author":"E Provenzano","year":"2015","unstructured":"Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C et al (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28(9):1185\u20131201","journal-title":"Mod Pathol"},{"issue":"1","key":"7906_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4132\/jptm.2020.11.20","volume":"55","author":"SY Cho","year":"2021","unstructured":"Cho SY, Park SY, Bae YK, Kim JY, Kim EK, Kim WG et al (2021) Standardized pathology report for breast cancer. J Pathol Transl Med 55(1):1\u201315","journal-title":"J Pathol Transl Med"},{"issue":"2","key":"7906_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdy547","volume":"30","author":"SJ Luen","year":"2019","unstructured":"Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE et al (2019) Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol 30(2):236\u2013242","journal-title":"Ann Oncol"},{"issue":"1","key":"7906_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10549-019-05437-z","volume":"179","author":"C Pinard","year":"2020","unstructured":"Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S et al (2020) Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 179(1):11\u201323","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"7906_CR31","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C et al (2021) The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol 32(10):1236\u20131244","journal-title":"Ann Oncol"},{"issue":"1","key":"7906_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12962-8","volume":"24","author":"NB Baharun","year":"2024","unstructured":"Baharun NB, Adam A, Zailani MAH, Rajpoot NM, Xu Q, Zin RRM (2024) Automated scoring methods for quantitative interpretation of tumour infiltrating lymphocytes (TILs) in breast cancer: a systematic review. BMC Cancer 24(1):1202","journal-title":"BMC Cancer"},{"issue":"22","key":"7906_CR33","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147\u20132159","journal-title":"N Engl J Med"},{"key":"7906_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104477","volume":"81","author":"Y Ma","year":"2025","unstructured":"Ma Y, Zhu M, Zhang J, Jiao D, Hou Y, Chen X et al (2025) Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study. Breast 81:104477","journal-title":"Breast"},{"issue":"5","key":"7906_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai L, Denkert C, O\u2019Shaughnessy J, Cortes J, Dent R, McArthur H et al (2024) Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol 35(5):429\u2013436","journal-title":"Ann Oncol"},{"issue":"3","key":"7906_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3857\/roj.2024.00087","volume":"42","author":"H Park","year":"2024","unstructured":"Park H, Kim H, Park W, Cho WK, Kim N, Kim TG et al (2024) Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapy. Radiat Oncol J 42(3):210\u2013217","journal-title":"Radiat Oncol J"},{"issue":"3","key":"7906_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ijrobp.2022.03.007","volume":"113","author":"RB Mailhot Vega","year":"2022","unstructured":"Mailhot Vega RB, Wang S, Brooks ED, Oladeru OT, Lockney NA, Spiguel LE et al (2022) Evaluating regional nodal irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40, and B-41. Int J Radiat Oncol Biol Phys 113(3):542\u2013551","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"21","key":"7906_CR38","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kummel S et al (2024) Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 391(21):1981\u20131991","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07906-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:28:54Z","timestamp":1770802134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07906-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7906"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07906-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The requirement for informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study was approved by the Institutional Review Board of Samsung Medical Center (approval number 2024-02-110).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"76"}}